Literature DB >> 17869012

Contribution of TIA-1+ and granzyme B+ cytotoxic T lymphocytes to cryptal apoptosis and ulceration in active inflammatory bowel disease.

Hiroyuki Mitomi1, Yasuo Ohkura, Kaoru Yokoyama, Miwa Sada, Kiyonori Kobayashi, Satoshi Tanabe, Naoshi Fukui, Hideki Kanazawa, Ichiro Kishimoto, Katsunori Saigenji.   

Abstract

In spite of the clinicopathological differences between Crohn's disease (CD) and ulcerative colitis (UC), they share the fundamental feature of destructive inflammatory processes involving the intestinal wall. The aim of the present study was to investigate the contribution of cell-mediated cytotoxicity to mucosal damage in CD and UC. Colonic mucosal biopsy specimens from patients with active CD (n=25) and UC (n=26) and normal controls (n=12) were immunohistochemically analyzed for the expression of CD3, CD4, CD8, and T cell-restricted intracellular antigen (TIA)-1, which promotes apoptosis by alternative splicing of pre-messenger RNA of the Fas receptor, and granzyme B (GrB), which leads to apoptosis through induction of perforin. Histological scores for cryptal apoptosis and ulceration were assessed in hematoxylin- and eosin-stained sections. In patients with CD and UC, CD3+(P<0.001), CD4+(P<0.001), CD8+(P<0.01), TIA-1+(CD, P<0.01; UC, P<0.001), and GrB+(CD, P<0.01; UC, P<0.001) intraepithelial lymphocytes (IELs) were significantly increased as compared with controls. Positive relationships were found between the histological scores for apoptosis or ulceration and the numbers of CD8+or TIA-1+IELs. In conclusion, cytotoxic T lymphocytes are present in increased numbers in the mucosa of patients with active CD and UC, and local activation of IELs may contribute to mucosal damage with these diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17869012     DOI: 10.1016/j.prp.2007.06.007

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  3 in total

Review 1.  T-cell intracellular antigens in health and disease.

Authors:  Carmen Sánchez-Jiménez; José M Izquierdo
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 2.  Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease.

Authors:  M T Tang; M E Keir; R Erickson; E G Stefanich; F K Fuh; T Ramirez-Montagut; J M McBride; D M Danilenko
Journal:  Aliment Pharmacol Ther       Date:  2018-03-30       Impact factor: 8.171

Review 3.  Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma.

Authors:  Wendy Anne Boivin; Dawn Michelle Cooper; Paul Ryan Hiebert; David James Granville
Journal:  Lab Invest       Date:  2009-09-21       Impact factor: 5.502

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.